Sarepta Therapeutics, Inc.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.9B
- Net income
- -$713.4M
- Total assets
- $3.3B
- Market cap
- $1.7B
- Gross margin
- 98.8%
- Operating margin
- -31.8%
- Net margin
- -32.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2B
- Cost of revenue
- $25.5M
- Gross profit
- $2.2B
- Operating expenses
- $2.9B
- Operating income
- -$699.8M
- Income tax
- $11.2M
- Net income
- -$713.4M
- EPS (basic)
- $-7.13
- EPS (diluted)
- $-7.13
Balance sheet
- Total assets
- $3.3B
- Current assets
- $2.5B
- Total liabilities
- $2.2B
- Current liabilities
- $1.1B
- Shareholders’ equity
- $1.1B
Cash flow
- Operating cash flow
- -$205.5M
- Investing cash flow
- $69.6M
- Financing cash flow
- -$168.3M
- Net cash flow
- -$304.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-7.13
- Shares outstanding
- 106.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 4, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $713.4M in FY2025.
- Revenue grew 213% from FY2021 to FY2025.
- Gross margin of 98.8%, net margin -32.5%.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Sarepta Therapeutics, Inc..
Write a review
News about Sarepta Therapeutics, Inc.
News & sentiment via Polygon.io
